Literature DB >> 19057266

Combined evaluation of postoperative serum levels of carcinoembryonic antigen less than or equal to 2.5 ng/ml and absence of vascular invasion may predict no recurrence of stage I adenocarcinoma lung cancer.

Kosuke Kashiwabara1, Syoh Saeki, Ji-ichiro Sasaki, Masanobu Nomura, Hirotsugu Kohrogi.   

Abstract

STUDY
OBJECTIVES: It has been reported that high levels of serum carcinoembryonic antigen (CEA) after surgery, or the presence of vascular invasion or both, are strong indicators of postoperative recurrence in patients with non-small cell lung cancer. The purpose of this study is to evaluate which kind of patients with p-stage I adenocarcinoma need adjuvant chemotherapy, using those predictors. PATIENTS AND METHODS: We studied 136 patients with curatively resected p-stage I adenocarcinoma during the 7-year period of January 1, 2000 to December 31, 2006. Receiver operating characteristics curves were constructed using postoperative CEA levels measured 2 months after surgery. Clinical variables were examined as possible predictors of disease recurrence by multivariate analysis using the Cox proportional-hazards model.
RESULTS: The median time of follow-up after surgery was 28.3 months. Fifteen (11%) of 136 patients had postoperative recurrence (7 p-stage IA cases and 8 p-stage IB cases). The presence of vascular invasion (hazard ratio: 10.229, 95% confidence intervals: 2.811-37.223, p = 0.0004) and high postoperative CEA levels (hazard ratio: 1.650, 95% confidence intervals: 1.196-2.275, p = 0.0023) increased the risk of recurrence. There was no recurrence in patients who had both postoperative CEA levels less than or equal to 2.5 ng/ml and no vascular invasion.
CONCLUSION: Combined evaluation of postoperative CEA levels and vascular invasion makes it possible to predict disease recurrence in the curatively resected p-stage I adenocarcinoma patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19057266     DOI: 10.1097/JTO.0b013e31818dda85

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  8 in total

1.  Expression and prognostic relevance of tumor carcinoembryonic antigen in stage IB non-small cell lung cancer.

Authors:  Jian Wang; Yun Ma; Zhi-Hua Zhu; Dong-Rong Situ; Yi Hu; Tie-Hua Rong
Journal:  J Thorac Dis       Date:  2012-10       Impact factor: 2.895

Review 2.  Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers.

Authors:  Philip A J Crosbie; Rajesh Shah; Yvonne Summers; Caroline Dive; Fiona Blackhall
Journal:  Transl Lung Cancer Res       Date:  2013-10

Review 3.  Blood vessel invasion as a strong independent prognostic indicator in non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Jun Wang; Jianpeng Chen; Xi Chen; Baocheng Wang; Kainan Li; Jingwang Bi
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

4.  Development and validation of a preoperative prognostic index independent of TNM stage in resected non-small cell lung cancer.

Authors:  Shogo Kumagai; Satoshi Marumo; Machiko Arita; Keiji Yamanashi; Ryota Sumitomo; Yosuke Otake; Tsuyoshi Shoji; Motonari Fukui; Toshiro Katayama; Norihito Okumura; Cheng-Long Huang
Journal:  BMC Pulm Med       Date:  2017-12-04       Impact factor: 3.317

5.  Dynamic monitoring serum tumor markers to predict molecular features of EGFR-mutated lung cancer during targeted therapy.

Authors:  Zhuxing Chen; Liping Liu; Feng Zhu; Xiuyu Cai; Yi Zhao; Peng Liang; Limin Ou; Ran Zhong; Ziwen Yu; Caichen Li; Jianfu Li; Shan Xiong; Yi Feng; Bo Cheng; Hengrui Liang; Zhanhong Xie; Wenhua Liang; Jianxing He
Journal:  Cancer Med       Date:  2022-05-11       Impact factor: 4.711

6.  Prognostic significance of postoperative serum carcinoembryonic antigen levels in patients with completely resected pathological-stage I non-small cell lung cancer.

Authors:  Yoshiki Kozu; Tomohiro Maniwa; Shoji Takahashi; Mitsuhiro Isaka; Yasuhisa Ohde; Takashi Nakajima
Journal:  J Cardiothorac Surg       Date:  2013-04-22       Impact factor: 1.637

7.  Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Authors:  Yu-Mu Chen; Chien-Hao Lai; Huang-Chih Chang; Tung-Ying Chao; Chia-Cheng Tseng; Wen-Feng Fang; Chin-Chou Wang; Yu-Hsiu Chung; Kuo-Tung Huang; Hung-Cheng Chen; Ya-Chun Chang; Meng-Chih Lin
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

8.  Serum dickkopf-1 as a clinical and prognostic factor in non-small cell lung cancer patients with bone metastases.

Authors:  Rong Qiao; Runbo Zhong; Qing Chang; Jiajun Teng; Jun Pei; Baohui Han; Tianqing Chu
Journal:  Oncotarget       Date:  2017-06-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.